Update on the treatment for advanced HCC With more than 900,000 newly diagnosed cases in 2020, hepatocellular carcinoma (HCC) is the sixth most frequent malignant disease with a high mortality rate of approximately 92 % [1].

Towards treating all stages of gastric cancer and gastroesophageal junction adenocarcinoma Gastric and esophagus cancers were the fifth and the seventh most frequently diagnosed cancers worldwide in 2020, respectively.

From neoadjuvant to second-line therapeutic options for RCC patients Kidney cancer accounted for more than 400,000 newly diagnosed cases in 2020, [1].

Promising therapeutic strategies for colorectal cancer treatment With more than 1.9 million new cases, colorectal cancer (CRC) accounted in 2020 for 10 % of all diagnosed cancers. CRC ranked third in terms of incidence and was the second leading cause of cancer mortality worldwide, with 935,000 estimated deaths in 2020 [1].

Novel early clinical approaches in solid tumors CLDN6 CAR-T cell therapy - Encouraging results Chimeric antigen receptor (CAR)-T cells have proven to be effective in the clinic for patients with malignant B-cell tumors but their application for solid tumors is challenging [1]. BNT211 is a novel therapeutic approach which comprises two components: CAR-T cells targeting the Claudin 6 (CLDN6) and a CLDN6-encoding CAR-T cell amplifying RNA vaccine (CARVac) [2]. On June 23, 2022, BNT211 has recei

Preface – ESMO 2020 Solid Tumors Ronan Kelly, MD, MBA – Director of the Charles A. Sammons Cancer Center at Baylor University Medical Center – Dallas, Texas, USA Dear Colleagues, Notable advances that have been achieved in the treatment of solid tumors were discussed at the virtual ESMO Congress 2020, among them remarkable results obtained in the field of gastroesophageal tumors.

Milestones of PD-1 inhibition in gastric and esophageal cancer Gastric cancer, gastroesophageal junction (GEJ) adenocarcinoma, and esophageal adenocarcinoma are substantial causes of cancer-related mortality worldwide and have poor 5-year overall survival (OS) when diagnosed at an advanced stage [1, 2].

Getting innovation from the laboratories into clinical practice Andrés Cervantes, MD, PhD, Department of Medical Oncology, Hospital Clinic Universitario, Biomedical Research institute INCLIVA, University of Valencia, Spain Which data presented at ESMO 2020 in the field of gastric cancer, gastro­eso­phageal junction adeno­carcinoma and esophageal cancer do you deem practice-changing? The ESMO congress has provided amazing new data on gastroesophageal cancer, and great contributions by

Ovarian cancer: taking PARP inhibition one step further Individualized dosing of niraparib Niraparib has been approved as maintenance treatment for patients with plat­inum-sensitive recurrent ovarian cancer (OC) based on the results of the NOVA trial [1]. The starting dose used in NOVA was 300 mg orally daily.

Novel combination approaches in various solid tumors Lenvatinib plus pembrolizumab The anti-angiogenic multikinase in­hibitor lenvatinib has been shown to ­exert immunomodulatory effects that enhance the anti-tumor activity of anti-PD-1 antibodies [1]. In the early-phase setting, lenvatinib plus pembrolizumab induced partial responses in patients with different tumor types [2].